A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494

To assess the safety, tolerability and pharmacokinetics of ABT-494 in healthy volunteers and
in patients with rheumatoid arthritis.

Inclusion Criteria:

Healthy Volunteers:

- Male and female subjects 18 to 55 years of age, inclusive.

- Subject is judged to be in good general health.

Rheumatoid Arthritis Patients:

- Male and female patients 18 to 75 years of age, inclusive.

- Subject has a diagnosis of rheumatoid arthritis for at least six months.

- Subject has been on methotrexate therapy for at least three months and on a stable
dose for at least four weeks.

Exclusion Criteria:

- History or evidence of active or latent tuberculosis.

- History or significant allergic reaction to any drug.

- Use of known strong CYP3A and CYP2D6 inhibitors and CYP3A inducers within 21 days or
within 5 half-lives of the respective medication, whichever is longer.

- Current or expected need for oral intake of at least 10 mg prednisone per day or
equivalent corticosteroid therapy.

- History of acute inflammatory joint disease of different origin other than rheumatoid
arthritis (rheumatoid arthritis patients).